Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to outsmart Drug-Resistant prostate cancer

NCT ID NCT06705686

Recruiting now Disease control Sponsor: TechnoGenesys, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times

Summary

This early-phase study tests a new oral medication, (R)-9bMS, in about 18-30 men with metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to standard hormone therapy). The drug works by blocking a protein called ACK1, which may help shrink tumors and boost the immune system against cancer cells. The main goal is to check safety and find the best dose, while also looking at how well it controls the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA